GLP-1 receptor agonists, the medications behind Ozempic and similar diabetes and weight loss drugs, are drawing attention for a possible new benefit: lowering cancer risk. U.S. News & World Report reports on early research suggesting these drugs may be linked to a reduced risk of several obesity related cancers, including breast, colorectal and liver cancer. Experts describe the findings as promising but stress that they are still preliminary.
Much of the potential benefit, researchers believe, comes from improving the metabolic conditions that help many cancers take hold. By promoting healthy weight loss, calming chronic inflammation, lowering estrogen levels after menopause, and improving insulin sensitivity, GLP-1s may address the underlying drivers of obesity related cancer. Some early laboratory studies also point to more direct effects, such as slowing the growth of certain cancer cells, though scientists caution that much more work is needed to understand them.
Of particular relevance to liver health, the article highlights research led by Stanford’s Professor Mindie Nguyen suggesting that GLP-1 use may help lower liver cancer risk in people at high risk, specifically those with Type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). Even so, experts are careful to note that these medications are not FDA-approved for cancer prevention and should not be viewed as a substitute for proven prevention strategies.
The overall message from oncology experts is one of cautious optimism. The data are encouraging, but they come largely from retrospective studies that show association rather than proof of cause. For now, anyone concerned about cancer risk is advised to stay current with established screening guidelines and to discuss their metabolic health with a doctor. For people at elevated risk of liver cancer, early detection remains essential, and that is where Helio Genomics focuses its blood based diagnostics.
Source: U.S. News & World Report. Read the full article.